AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20479419
Drug: Doxorubicin 50
RxNorm normalized name: DOXOrubicin 50 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 50 mg/m² plus paclitaxel 200 mg/m² every 3 weeks for four cycles followed by paclitaxel 80 mg/m² weekly for 12 weeks (AP-WP)
Trial: 18705538
Drug: 600 mg/day
RxNorm normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/day oral magnesium citrate supplementation
Trial: 8959632
Drug: Calcium mupirocin
RxNorm normalized name: Mupirocin Calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium mupirocin 2% (Bactroban nasal) applied twice daily for 5 consecutive days every 4 weeks
Trial: 8959632
Drug: Placebo ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ointment applied twice daily for 5 consecutive days every 4 weeks
Trial: 6122004
Drug: Opsonisation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opsonisation of T lymphocytes with 1 mg of the murine monoclonal antibody OKT3 before infusion
Trial: 31012850
Drug: Prediction score
RxNorm normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prediction score model for CC GW crossing success
Trial: 27283723
Drug: Intra-space injection
RxNorm normalized name: somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra-space injection of dexamethasone (4 mg) with 2% lignocaine and 1:200,000 epinephrine (SS)
Trial: 27283723
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of dexamethasone (4 mg) with standard inferior alveolar nerve block (CS)
Trial: 25248371
Drug: Exclusive oral-feeding
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exclusive oral-feeding supply
Trial: 16218173
Drug: Saquinavir/ritonavir (SAQ/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saquinavir/ritonavir (SAQ/r) 1000/100 mg twice daily
Trial: 9773732
Drug: BCG vaccination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG vaccination (0.1 ml, 100 microg)
Trial: 9773732
Drug: Control (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0.1 ml saline)
Trial: 8011827
Drug: Prophylactic antibiotics
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic antibiotics administration
Trial: 3072016
Drug: Morphine 10
RxNorm normalized name: morphine 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 10 mg alone
Trial: 30511963
Drug: High-dose live
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose live attenuated VZV vaccine
Trial: 25574795
Drug: Progesterone for
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Progesterone for the Treatment of Traumatic Brain Injury
Trial: 17910651
Drug: Early steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early steroid withdrawal (decreasing steroid doses stopping at day 7 post-transplant)
Trial: 17910651
Drug: Early steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early steroid withdrawal
Trial: 17910651
Drug: Steroid-based control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid-based control group (CsA, AZT)
Trial: 17910651
Drug: Steroid-based control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid-based control group
Trial: 9513957
Drug: Paravertebral blockade
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paravertebral blockade (steroid + local anaesthetic)
Trial: 9513957
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (spine-decompressing position, traction, therapeutic exercises)
Trial: 29773818
Drug: Anti-malarial compounds
RxNorm normalized name: malarial plasmodium group immunoserum rabbit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-malarial compounds in EIA
Trial: 29773818
Drug: pIC50 for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pIC50 for 11 different compounds in EIA
Trial: 21211323
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (NAC) administered for 1 - 3 cycles before radical hysterectomy and lymphadenectomy.
Trial: 21211323
Drug: Director operation
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Director operation (DOR) without prior chemotherapy, radical hysterectomy performed directly after diagnosis.
Trial: 16009171
Drug: Raloxifene 180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene 180 mg/day orally for three cycles of 28 days
Trial: 16009171
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets (3 tablets/day orally)
Trial: 2878597
Drug: Bevantolol 400
RxNorm normalized name: bevantolol
DrugBank: Bevantolol (DB01295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevantolol 400 mg
Trial: 30922101
Drug: Single ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single ketamine infusion
Trial: 31759333
Drug: Repeated ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated ketamine infusions (six infusions thrice-weekly over 2 weeks)
Trial: 31759333
Drug: Maintenance infusions
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance infusions (four further infusions once-weekly)
Trial: 30175606
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid (third administration)
Trial: 21182551
Drug: Active gum
RxNorm normalized name: STANNOUS FLUORIDE 1.1 mg in 1 g DENTAL PASTE [parodontax Active Gum Repair]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active gum (2 mg or 4 mg)
Trial: 21182551
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (2 mg or 4 mg)
Trial: 17446413
Drug: Intralipid (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralipid (0.8 ml x m(‐2) x min(‐1)) and heparin (1,000 U/h)
Trial: 17446413
Drug: Saline (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (0.8 ml x m(‐2) x min(‐1)) and heparin (1,000 U/h)
Trial: 8130921
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine patches (delivering 15 mg over 16 hours) with low-intensity support
Trial: 31650529
Drug: Active iliopsoas
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active iliopsoas plane block (5 mL lidocaine 18 mg/mL with epinephrine)
Trial: 29313751
Drug: 2-dose-ZW (28
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-dose-ZW (28 g)
Trial: 29313751
Drug: 1-dose-ZW (14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-dose-ZW (14 g)
Trial: 28088231
Drug: Gabapentin (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (maximum of 1800 mg/day for 5 weeks)
Trial: 11243947
Drug: Salmeterol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol (50 microg, twice daily)
Trial: 16893984
Drug: 50 microg
RxNorm normalized name: Digoxin 250 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 microg PS vaccinating dose
Trial: 9009369
Drug: 0.04% mitomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.04% mitomycin C eye drops, four times daily for two weeks or longer after surgery
Trial: 25189175
Drug: Hypertonic sodium
RxNorm normalized name: Sodium Chloride Topical application Dressing [CURITY HYPERTONIC SODIUM CHLORIDE PACKING STRIP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic sodium lactate solution (HSL) - 5 ml/kg/BW in 15 minutes followed by 1 ml/kg/BW/h for 12 hours
Trial: 25189175
Drug: Ringer lactate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer lactate (RL) - 20 ml/kg/BW in 15 minutes followed by decreasing doses of 10, 7, 5, and 3 ml/kg BW/h for 12 hours
Trial: 25189175
Drug: Hypertonic sodium
RxNorm normalized name: Sodium Chloride Topical application Dressing [CURITY HYPERTONIC SODIUM CHLORIDE PACKING STRIP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic sodium lactate solution (HSL)
Trial: 16359401
Drug: Vi polysaccharide
RxNorm normalized name: Typhoid Vi polysaccharide vaccine
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vi polysaccharide (PS) vaccine
Trial: 11953977
Drug: Pulse cyclophosphamide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulse cyclophosphamide, pulse methylprednisolone, or the combination of both
Trial: 11953977
Drug: Additional immunosuppressive
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional immunosuppressive therapy
Trial: 7824101
Drug: L/R HF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L/R HF ratios
Trial: 19621834
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy with exposure and response prevention
Trial: 19621834
Drug: Augmentation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmentation of SSRI with atypical antipsychotic
Trial: 3981411
Drug: Repeat-action combination
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeat-action combination tablet containing 6 mg of dexbrompheniramine maleate with 120 mg of pseudoephedrine sulfate every 12 h for 7 d
Trial: 3981411
Drug: Concomitant administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concomitant administration of conventional 2-mg dexbrompheniramine maleate tablets every 4 h and 120-mg pseudoephedrine sulfate repeat-action tablets every 12 h, each for 7 d
Trial: 27589059
Drug: MD1003 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MD1003 (100 mg biotin)
Trial: 22348492
Drug: 5mg/kg oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg/kg oral erythromycin every 6 hours for 14 days (n=19)
Trial: 19136327
Drug: Psychoeducational intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Psychoeducational intervention to reduce severity of oral mucositis and oral pain
Trial: 12363116
Drug: Cognitive‐behavioral therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive‐behavioral therapy plus paroxetine (40 mg/day)
Trial: 12363116
Drug: Cognitive‐behavioral therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive‐behavioral therapy plus placebo
Trial: 7721239
Drug: Granular (G)
RxNorm normalized name: Saxifraga granulata whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granular (G) type duodenitis
Trial: 2481775
Drug: Felodipine-ER 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine-ER 10 mg
Trial: 2481775
Drug: Felodipine-ER 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine-ER 20 mg
Trial: 1234484
Drug: Trazodone (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone (single oral dose)
Trial: 23193217
Drug: Closed-loop basal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed-loop basal insulin delivery
Trial: 21632228
Drug: Glycopyrrolate 0.4
RxNorm normalized name: glycopyrrolate 0.4 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate 0.4 mg
Trial: 17566124
Drug: Levetiracetam (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam (maximum dose 30 mg/kg/day)
Trial: 12116023
Drug: Famciclovir 500
RxNorm normalized name: famciclovir 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famciclovir 500 mg three times a day
Trial: 9537221
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg azimilide orally each day
Trial: 9537221
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg azimilide orally each day
Trial: 2675895
Drug: Azathioprine (AZA;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine (AZA; 2 mg/kg per day) in combination with CyA (group AZA+)
Trial: 593193
Drug: Triphasic preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triphasic preparation with a sequence of 6/5/10
Trial: 593193
Drug: Triphasic preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triphasic preparation with a reduced content of total dose of oestrogen per cycle
Trial: 25870057
Drug: BMS‐663068 at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS‐663068 at 600 mg BID
Trial: 25870057
Drug: BMS‐663068 at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS‐663068 at 600 mg BID plus RTV at 100 mg QD
Trial: 25870057
Drug: ATV/r (ATV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATV/r (ATV at 300 mg QD plus RTV at 100 mg QD)
Trial: 25870057
Drug: BMS‐663068 at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS‐663068 at 600 mg BID plus ATV at 300 mg QD plus RTV at 100 mg QD
Trial: 10179922
Drug: NSAID therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAID therapy (not specified)
Trial: 7917153
Drug: Human Ser-Tyr28
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human Ser-Tyr28 ANH (0.6 pmol/kg/min) infusion during low-salt diet (LS+ANH)
Trial: 7917153
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion during low-salt diet (LS)
Trial: 7917153
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion during high-salt diet (HS)
Trial: 2576363
Drug: picumast dihydrochloride
RxNorm normalized name: Levocetirizine Dihydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: picumast dihydrochloride 1 mg
Trial: 31789554
Drug: Alcoholic beverage
RxNorm normalized name: Alcoholic beverage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcoholic beverage (target BrAC = .08 g%)
Trial: 30496426
Drug: Good value
RxNorm normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Good value estimation methodology (total cholesterol of 170 mg/dl and HDL‐cholesterol of 50 mg/dl)
Trial: 27013221
Drug: Acceptance Commitment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance Commitment Therapy (ACT) intervention; 6 sessions
Trial: 26606003
Drug: High-volume injectate
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-volume injectate (8 mL)
Trial: 26606003
Drug: Low-volume injectate
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-volume injectate (3 mL)
Trial: 23368828
Drug: Caffeine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (5 mg/kg of body mass/day)
Trial: 19889067
Drug: EAC (esomeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EAC (esomeprazole 20 mg b.d., amoxycillin 1 g b.d., and clarithromycin 500 mg b.d.)
Trial: 19889067
Drug: EAL (esomeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EAL (esomeprazole 20 mg b.d., amoxycillin 1 g b.d., and levofloxacin 500 mg daily)
Trial: 17230483
Drug: Preoperative medication
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative medication responsiveness
Trial: 14764786
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment with dosages of 1 mg/m².d and 2 mg/m².d (approximately 0.035 and 0.070 mg/kg.d, respectively) for 1 year
Trial: 8997462
Drug: Topical antimicrobial
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical antimicrobial gels containing 4 times minimally inhibitory in vitro concentrations
Trial: 8997462
Drug: Topical antimicrobial
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical antimicrobial gels containing 8 times minimally inhibitory in vitro concentrations
Trial: 8203854
Drug: Aztreonam (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aztreonam (6 g/day [2 g intravenously every 8 h] for 10 days)
Trial: 8203854
Drug: Chloramphenicol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloramphenicol (50 mg/kg of body weight per day [intravenously or orally] for 14 days)
Trial: 3555596
Drug: PUVA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUVA with oral 8‐methoxypsoralen (8‐MOP)
Trial: 3555596
Drug: UVB with
RxNorm normalized name: ZINC OXIDE 20 g in 100 g TOPICAL LOTION [restorsea Rejuvenating Day SPF 30 Broad Spectrum UVA UVB with Vibransea Complex]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UVB with oral placebo
Trial: 3555596
Drug: Control low‐dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control low‐dose UVA with oral placebo
Trial: 31173464
Drug: High-intensity focused
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity focused ultrasound treatment
Trial: 16172545
Drug: Desipramine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desipramine (50 mg once daily)
Trial: 16172545
Drug: Escitalopram (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (10 mg once daily)
Trial: 345632
Drug: Meglumine iodamide
RxNorm normalized name: meglumine iodamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meglumine iodamide (0.8 cc/kg to a maximum of 55 cc)
Trial: 345632
Drug: Renografin 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renografin 60 (52% meglumine diatrizoate and 8% sodium diatrizoate) (0.8 cc/kg to a maximum of 55 cc)
Trial: 24322420
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of ATP injected before PVI in AF patients
Trial: 24322420
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of ATP injected in AVRT patients
Trial: 21960668
Drug: Ticagrelor (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor (180 mg single dose)
Trial: 17445634
Drug: Intravenous erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous erythromycin (125 mg) every 8 hours (maximum of 21 doses)
Trial: 19759966
Drug: Energy conservation
RxNorm normalized name: Senergy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Energy conservation training (1 to 2 hours of individual training followed by weekly telephone monitoring for 3 weeks)
Trial: 10555027
Drug: Sulfasalazine (SSZ)
RxNorm normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulfasalazine (SSZ) 2000 mg/day
Trial: 8707971
Drug: Active prescale
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active prescale gel
Trial: 8707971
Drug: Active prescale
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active prescale gel (extended exposure)
Trial: 1762068
Drug: 3.75 mg
RxNorm normalized name: zopiclone 3.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75 mg of morphine
Trial: 1762068
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg of morphine
Trial: 1762068
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg of morphine
Trial: 1762068
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of morphine
Trial: 1762068
Drug: Lowest dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lowest dose of morphine (not specified)
Trial: 1762068
Drug: Intermediate doses
RxNorm normalized name: Prevotella intermedia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate doses of morphine (not specified)
Trial: 1762068
Drug: Highest dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highest dose of morphine (30 mg)
Trial: 6347229
Drug: Metoprolol SA
RxNorm normalized name: metoprolol
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoprolol SA 200 mg once daily
Trial: 31389784
Drug: methyl‐5‐aminolevulinate 16%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: methyl‐5‐aminolevulinate 16% cream-Photodynamic therapy (PDT)
Trial: 31389784
Drug: imiquimod 5%
RxNorm normalized name: Imiquimod 5% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: imiquimod 5% cream
Trial: 27352310
Drug: Baicalein 200
RxNorm normalized name: Baicalein
DrugBank: Baicalein (DB16101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baicalein 200 mg once daily on days 1 and 10, twice daily on days 3-9
Trial: 27352310
Drug: Baicalein 400
RxNorm normalized name: Baicalein
DrugBank: Baicalein (DB16101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baicalein 400 mg once daily on days 1 and 10, twice daily on days 3-9
Trial: 27352310
Drug: Baicalein 800
RxNorm normalized name: Baicalein
DrugBank: Baicalein (DB16101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baicalein 800 mg once daily on days 1 and 10, twice daily on days 3-9